Cancer patients who develop thrombosis and/or pulmonary embolism can replace their daily injections of low molecular weight heparin with a warfarin pill after the first six months of treatment. That’s what a study done by Dr. Chatree Chai-Adisaksopha, of McMaster University (Ontario, Canada), shows based on data of the RIETE registry.

The specialist observed the evolution of 1.502 patients to whom the RIETE doctors administered warfarine (an oral anticoagulant) after half a year with the usual treatment, low molecular weight heparin. As well as being less aggressive for the patient, oral treatment did not increase the risk of a new thromboembolic episode and neither the risk of bleeding.

Results of this study, showed in the annual conference of the American Society of Hematology (ASH) confirm a practice that other professionals have been practicing. Warfarin is not harmful and it is a good option after those first six months in which the patient must have low molecular weight heparin injections.

So far, this is a very little explored practice, since there were very few data. The RIETE registry, a database with information of roughly 60.000 patients with venous thromboembolic disease, promoted by FUENTE foundation, has allowed us to reach to this conclusion.


<a class="twitter-timeline" href="" data-widget-id="679613306152316928">Tuits de @tromboinfo</a> <script>!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);;js.src=p+"://";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");</script>